{
    "Question": "Should patients with RA on oral MTX monotherapy 15 mg per week who are NOT at target increase the dose of oral MTX or switch to SC MTX?",
    "Comparison": 
    {
        "Switch to SC MTX versus Increase the dose of oral MTX.": 
        {   "filename": "PICO 18_Comparison 1.json",
            "Explanations": 
            {
                "a": "Downgraded by two levels due to very serious risk of bias. Lack of blinding and lack of allocation concealment.",
                "b": "Downgraded by one level due to serious imprecision. Very small sample size.",
                "c": "SC 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.",
                "d": "PO 20mg MTX for 4 weeks, then 25mg MTX for 8 weeks.",
                "e": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size."
            }
        }
    },
    "References": 
    {
        "1": "Islam MS, Haq SA, Islam MN, Azad AK, Islam MA, Barua. Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis. Mymensingh Medical Journal: MMJ. 2013;22(3):483."
    }
}